Drug Detail:Givlaari (Givosiran [ gi-voe-si-ran ])
Generic Name: givosiran sodium 189mg in 1mL
Dosage Form: injection, solution
Drug Class: Miscellaneous metabolic agents
Drug Detail:Givlaari (Givosiran [ gi-voe-si-ran ])
Generic Name: givosiran sodium 189mg in 1mL
Dosage Form: injection, solution
Drug Class: Miscellaneous metabolic agents
The recommended dose of GIVLAARI is 2.5 mg/kg administered via subcutaneous injection once monthly. Dosing is based on actual body weight.
Missed Dose
Administer GIVLAARI as soon as possible after a missed dose. Resume dosing at monthly intervals following administration of the missed dose.
Dose Modification for Adverse Reactions
In patients with severe or clinically significant transaminase elevations, who have dose interruption and subsequent improvement, reduce the dose to 1.25 mg/kg once monthly [see Warnings and Precautions (5.2)]. In patients who resume dosing at 1.25 mg/kg once monthly without recurrence of severe or clinically significant transaminase elevations, the dose may be increased to the recommended dose of 2.5 mg/kg once monthly.
Ensure that medical support is available to appropriately manage anaphylactic reactions when administering GIVLAARI [see Warnings and Precautions (5.1)].
GIVLAARI is intended for subcutaneous use by a healthcare professional only.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. GIVLAARI is a sterile, preservative-free, clear, colorless-to-yellow solution. It is supplied in a single-dose vial, as a ready-to-use solution that does not require additional reconstitution or dilution prior to administration.
Use aseptic technique.